GigaGen is a talented team of clinicians, bioinformaticians, microfluidics engineers, molecular biologists, and diagnostics experts.

We envision a future where doctors routinely use an immune "fingerprint" to help manage complex medical problems such as transplantation, inflammatory bowel disease, and multiple sclerosis.

We are funded by seed capital from Sequoia Capital and Claremont Creek Ventures. We have also won grants from NIH, NSF, and DOE.

The GigaMune technology combines microfluidics, next-generation sequencing, and bioinformatics to digitize your immune system into an immune "fingerprint".

Hundreds of single T or B cells per second are isolated into reaction compartments and then analyzed at key immune genes.

GigaMune will enable clinicians to diagnose and monitor a variety of pressing medical conditions that affect the immune system.

Cell-Seq is a generic platform that enables massively parallel single cell genetic analysis. We are first commercializing Cell-Seq as GigaMune, but many applications are possible.

Future work will develop the technology for noninvasive molecular analysis of cancer, and even development of immune therapeutics.

Our first customers are clinical researchers at Stanford University Medical Center who are studying graft-versus-host-disease (GVHD). Contact us for information on collaborations.